A program pairing academic medical institutions with managed care companies teaches residents how health plans work and to work with them.
And now, a 'report card' from the doctors
Drug Makers Put Half of Ad Money Into Television
Headlines on Deadline...
New Drugs, Greater Utilization Drive Rx Costs
What's the risk in risk?
Where's the Beef? Despite Predictions, Premiums Advance Only 3.3 Percent
Our other journal
P&T Journal for November 2014
LETTER TO THE EDITOR
Medications for Parkinson’s Disease
The Changing Roles of P&T Committees
Epilepsy Management: Newer Agents, Unmet Needs, and Future Treatment Strategies
Modest Growth Seen in Epilepsy Market
European Society of Cardiology and Transcatheter Cardiovascular Therapeutics
“Generic: The Unbranding of Modern Medicine,” by Jeremy A. Greene, MD, PhD
Misadministration of IV Insulin Associated With Dose Measurement And Hyperkalemia Treatment
FDA’s Proposed 503B Draft Compounding Guidance Raises Concerns of All Kinds
New Drugs/Drug News
Pharmaceutical Approval Update
Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension